Jun 02, 2025
Orexo to present clinical data for OX640 at the EAACI Congress
Apr 10, 2025
Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
Jan 10, 2025
Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
Oct 25, 2024
Orexo initiates new study of OX640 in participants with allergic rhinitis
Oct 24, 2024
Orexo Interim Report Q3 2024
Jul 10, 2024
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
May 10, 2024
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
May 08, 2024
Orexo Q1 2024 Interim Report
Apr 26, 2024
Report from Orexo AB's annual general meeting, 26 April 2024
Apr 17, 2024
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
Apr 02, 2024
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
Apr 02, 2024
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
Mar 08, 2024
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
Feb 12, 2024
Orexo and Sobi agree to advance feasibility study with AmorphOX
Feb 06, 2024
Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC
Feb 10, 2021
Orexo starts to test modia(TM) on patients in collaboration with ApexB.io and Magellan Rx Management
Jan 28, 2021
Orexo Q4 2020, incl. Full Year Report
Jan 27, 2021
Orexo strengthens IP rights for overdose rescue drug OX124
Dec 30, 2020
Orexo announces new US patent for ZUBSOLV®
Dec 07, 2020
Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV® in Europe